BACKGROUND: Familial testicular germ cell tumors (FTGCTs) are hypothesized to result from the combined interaction of multiple low-penetrance genes. We reported inactivating germline mutations of the cAMP-binding phosphodiesterase 11A (PDE11A) as modifiers of FTGCT risk. Recent genome-wide association studies have identified single-nucleotide polymorphisms in the KITLG gene, the ligand for the cKIT tyrosine kinase receptor, as strong modifiers of susceptibility to both familial and sporadic testicular germ cell tumors. DESIGN: We studied 94 patients with FTGCTs and 50 at-risk male relatives from 63 unrelated kindreds, in whom the PDE11A gene had been sequenced by investigating the association between KITLG genome-wide association study single-nucleotide polymorphisms rs3782179 and rs4474514 and FTGCT risk in these patients and in 692 controls. We also examined cAMP and c-KIT signaling in testicular tissues and cell lines and extended the studies to 2 sporadic cases, one with a PDE11A defect and one without, as a comparison. RESULTS: We found a higher frequency of the KITLG risk alleles in FTGCT patients who also had a PDE11A sequence variant, compared with those with a wild-type PDE11A sequence. In NTERA-2 and Tcam-2 cells transfected with the mutated forms of PDE11A (R52T, F258Y, Y727C, R804H, V820M, R867G, and M878V), cAMP levels were significantly higher, and the relative phosphodiesterase activity was lower than in the wild-type cells. KITLG expression was consistently increased in the presence of PDE11A-inactivating defects, both at the RNA and protein levels, in familial testicular germ cell tumors. The 2 sporadic cases that were studied, one with a PDE11A defect and another without, agreed with the data in FTGTCT and in the cell lines. CONCLUSIONS: Patients with FTGCT and PDE11A defects also carry KITLG risk alleles more frequently. There may be an interaction between cAMP and c-KIT signaling in predisposition to testicular germ cell tumors.
BACKGROUND:Familial testicular germ cell tumors (FTGCTs) are hypothesized to result from the combined interaction of multiple low-penetrance genes. We reported inactivating germline mutations of the cAMP-binding phosphodiesterase 11A (PDE11A) as modifiers of FTGCT risk. Recent genome-wide association studies have identified single-nucleotide polymorphisms in the KITLG gene, the ligand for the cKIT tyrosine kinase receptor, as strong modifiers of susceptibility to both familial and sporadic testicular germ cell tumors. DESIGN: We studied 94 patients with FTGCTs and 50 at-risk male relatives from 63 unrelated kindreds, in whom the PDE11A gene had been sequenced by investigating the association between KITLG genome-wide association study single-nucleotide polymorphisms rs3782179 and rs4474514 and FTGCT risk in these patients and in 692 controls. We also examined cAMP and c-KIT signaling in testicular tissues and cell lines and extended the studies to 2 sporadic cases, one with a PDE11A defect and one without, as a comparison. RESULTS: We found a higher frequency of the KITLG risk alleles in FTGCT patients who also had a PDE11A sequence variant, compared with those with a wild-type PDE11A sequence. In NTERA-2 and Tcam-2 cells transfected with the mutated forms of PDE11A (R52T, F258Y, Y727C, R804H, V820M, R867G, and M878V), cAMP levels were significantly higher, and the relative phosphodiesterase activity was lower than in the wild-type cells. KITLG expression was consistently increased in the presence of PDE11A-inactivating defects, both at the RNA and protein levels, in familial testicular germ cell tumors. The 2 sporadic cases that were studied, one with a PDE11A defect and another without, agreed with the data in FTGTCT and in the cell lines. CONCLUSIONS:Patients with FTGCT and PDE11A defects also carry KITLG risk alleles more frequently. There may be an interaction between cAMP and c-KIT signaling in predisposition to testicular germ cell tumors.
Authors: Christian P Kratz; Summer S Han; Philip S Rosenberg; Sonja I Berndt; Laurie Burdett; Meredith Yeager; Larissa A Korde; Phuong L Mai; Ruth Pfeiffer; Mark H Greene Journal: J Med Genet Date: 2011-05-26 Impact factor: 6.318
Authors: Katherine L Nathanson; Peter A Kanetsky; Rachel Hawes; David J Vaughn; Richard Letrero; Kathy Tucker; Michael Friedlander; Kelly-Anne Phillips; David Hogg; Michael A S Jewett; Radka Lohynska; Gedske Daugaard; Stéphane Richard; Agnés Chompret; Catherine Bonaïti-Pellié; Axel Heidenreich; Edith Olah; Lajos Geczi; Istvan Bodrogi; Wilma J Ormiston; Peter A Daly; J Wolter Oosterhuis; Ad J M Gillis; Leendert H J Looijenga; Parry Guilford; Sophie D Fosså; Ketil Heimdal; Sergei A Tjulandin; Ludmila Liubchenko; Hans Stoll; Walter Weber; Matthew Rudd; Robert Huddart; Gillian P Crockford; David Forman; D Timothy Oliver; Lawrence Einhorn; Barbara L Weber; Joan Kramer; Mary McMaster; Mark H Greene; Malcolm Pike; Victoria Cortessis; Chu Chen; Stephen M Schwartz; D Timothy Bishop; Douglas F Easton; Michael R Stratton; Elizabeth A Rapley Journal: Am J Hum Genet Date: 2005-10-24 Impact factor: 11.025
Authors: Catherine L Neary; Maria Nesterova; Yee Sook Cho; Chris Cheadle; Kevin G Becker; Yoon S Cho-Chung Journal: Oncogene Date: 2004-11-18 Impact factor: 9.867
Authors: E A Rapley; S Hockley; W Warren; L Johnson; R Huddart; G Crockford; D Forman; M G Leahy; D T Oliver; K Tucker; M Friedlander; K-A Phillips; D Hogg; M A S Jewett; R Lohynska; G Daugaard; S Richard; A Heidenreich; L Geczi; I Bodrogi; E Olah; W J Ormiston; P A Daly; L H J Looijenga; P Guilford; N Aass; S D Fosså; K Heimdal; S A Tjulandin; L Liubchenko; H Stoll; W Weber; L Einhorn; B L Weber; M McMaster; M H Greene; D T Bishop; D Easton; M R Stratton Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640
Authors: Anand Pathak; Douglas R Stewart; Fabio R Faucz; Paraskevi Xekouki; Sara Bass; Aurelie Vogt; Xijun Zhang; Joseph Boland; Meredith Yeager; Jennifer T Loud; Katherine L Nathanson; Katherine A McGlynn; Constantine A Stratakis; Mark H Greene; Lisa Mirabello Journal: Endocr Relat Cancer Date: 2015-12 Impact factor: 5.678
Authors: Mary L McMaster; Ketil R Heimdal; Jennifer T Loud; Janet S Bracci; Philip S Rosenberg; Mark H Greene Journal: Cancer Med Date: 2015-04-17 Impact factor: 4.452
Authors: Martin A Rijlaarsdam; David M J Tax; Ad J M Gillis; Lambert C J Dorssers; Devin C Koestler; Jeroen de Ridder; Leendert H J Looijenga Journal: PLoS One Date: 2015-04-10 Impact factor: 3.240
Authors: Marcela Rassi-Cruz; Andrea G Maria; Fabio R Faucz; Edra London; Leticia A P Vilela; Lucas S Santana; Anna Flavia F Benedetti; Tatiana S Goldbaum; Fabio Y Tanno; Vitor Srougi; Jose L Chambo; Maria Adelaide A Pereira; Aline C B S Cavalcante; Francisco C Carnevale; Bruna Pilan; Luiz A Bortolotto; Luciano F Drager; Antonio M Lerario; Ana Claudia Latronico; Maria Candida B V Fragoso; Berenice B Mendonca; Maria Claudia N Zerbini; Constantine A Stratakis; Madson Q Almeida Journal: Endocr Relat Cancer Date: 2021-01 Impact factor: 5.678